Real-world patient data gives valuable insights, such as collecting data on rare cancers and showing real-world side effects of treatment combinations. [Oakland, CA, May 26, 2023] – xCures, a healthcare technology company, is pleased to announce its participation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023, to… Read more »
Category: Uncategorized
Genome Medical and xCures Partner to Enhance Genetic Services with Personalized Clinical Data
Genome Medical and xCures have joined forces to provide patients with a new level of personalized care. Through this collaboration, Genome Medical’s genetic counselors will have access to xCures’ comprehensive care summaries for patients based on electronic medical records from across the healthcare ecosystem. This information will be used to… Read more »
xCures partners with RenovoRx to assist patients in accessing RenovoRx’s TIGeR-PaC study
RenovoRx’s Phase III clinical study is open to pancreatic adenocarcinoma patients and focuses on extending overall survival and improving quality of life. [EINPresswire] xCures, Inc. is proud to announce their partnership with RenovoRx, a clinical-stage biopharmaceutical company that focuses on fighting cancer through localized treatment of difficult-to-treat tumors, such as… Read more »
xCures Joins Big Names in Aetion’s New Initiative
xCures, a Real-Time Regulatory Grade Clinical Data (RRC) platform, will be joining Aetion, a global real-world evidence software and analytics provider, and a group of leading diverse partners in Aetion’s launch of the Coalition for the Advancement of RWE through Randomized Controlled Trial Emulation (CARE) Initiative. Aetion’s initiative will focus on better… Read more »
xCures presents clinical and translational research with two posters at the 2022 SNO Annual Meeting
XCELSIOR registry showcases its power in using real-world datasets and clinical outcomes to aid decision-making and treatment options for CNS cancer patients. [EIN Presswire] Today, xCures announced that they will present two posters at the 27th Annual Meeting of the Society for Neuro-Oncology, from the 16th to the 20th of… Read more »
Finally, cancer patients have real-time access to their medical records
Recent changes to patients’ data rights enable xCures’ platform to automatically retrieve patient medical records from institutions and generate powerful care summaries. EINPressWire, 11/8/22 Last month, the 21st Century Cures Act forced healthcare organizations to provide patients quick and easy access to their health records in a digital format. In… Read more »
xCures and mProbe partner to help cancer patients determine optimal treatments
xCures partners with mProbe, to leverage their targeted proteomics platform for profiling individual patients’ cancer tissues for actionable drug targets xCures, Inc. is proud to announce their collaboration with mProbe Inc., a premier CLIA-certified targeted proteomics company. mProbe utilizes a proprietary technology platform integrating artificial intelligence and multi-omic diagnostics to… Read more »
xCures and Oblato announce the launch of a Compassionate Use program for OKN-007
Oblato’s first-in-class small molecular OKN-007 will be available through a newly opened compassionate use protocol. xCures, Inc., a clinical study platform provider, and Oblato, Inc., a biotechnology company, are pleased to announce the availability of OKN-007 through an intermediate size expanded access program (iEAP) for eligible patients with pediatric diffuse… Read more »
